MAJOR RESEARCH INTERESTS:
Thrombosis and Vascular Biology
Innovations in Catheter-Based Treatment of Vascular Disease
Treatment of Myocardial Infarction
Platelet Activation in Heart Disease
Fibrinolytic Therapy/Platelet Activation
Antiplatelet Therapy/Mechanisms and Clinical Effects of Drug Resistance
Novel Pathways of Platelet-Platelet and Platelet-Leukocyte Interactions

The following research articles have been published in peer-reviewed journals within the last two years:

Peer-Reviewed Articles

Gurbel PA, Bliden KP, Hayes K, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev of  Cardiovasc Ther 2:535-45, 2005.

Samara WM, Bliden KP, Tantry U, Gurbel PA. Thrombotic risk: The difference between clopidogrel responsiveness and post-treatment platelet reactivity. Thromb Res 115:89-94, 2004. 

Gurbel PA, Hayes KA, Bliden KP, Yoho J, Tantry U. The platelet-related effects of tenecteplase vs. alteplase vs. reteplase. Blood Coag Fibrinolysis 16:1-7, 2005.

Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the CLEAR PLATELETS study. Circulation 111:1153-9, 2005.

Poston R, Gu J, Brown J, Gammie J, White C, Manchio J, Pierson RN, Griffith P, Gurbel P, Tantry U, Gilbert TB. Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass. J Cardiothoracic Vasc Anesth 19:11-18, 2005.

Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. Epub ahead of print. 2005.

Gurbel PA, Bliden KP, Hates KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 45:1392-6, 2005.

Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW; TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 45:1172-9, 2005.
.
Gurbel PA, Bliden KP, Samara W, Yoho J, Hayes K, Fissha M, Tantry U. Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis: Results of the CREST Study. J Am Coll Cardiol. 46:1827-32, 2005.

Gurbel PA, Bliden KP, Guyer K, Cho P, Zaman K, Kreutz R, Bassi A. Tantry US. Platelet REactivity in Patients And Recurrent Events POST-STENTING: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 46:1820-6, 2005.

Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: Current status and future research. Expert Opin Pharmacother 6:2027-45, 2005.

Tantry US, Bliden KP, Gurbel PA. What is the best predictor of thrombotic events: Pre-treatment platelet aggregation, clopidogrel responsiveness, or post-treatment aggregation? Cathet Cardiovasc Interv Oct 5 (epub ahead of print), 2005.

Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance: Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation. J Am Coll Cardiol. 46:1705-9, 2005.

Kreutz RP, Tantry US, Bliden KP, Gurbel PA. Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness. J Thromb Haemost 3:2108-9, 2005.

Bleske B, Nicklas J, Bard R, Brook R, Gurbel PA, Bliden K, Rajagopalan S, Pitt B. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins. J Am Coll Cardiol. 47:338-41, 2006.

Gurbel P, Singh D. Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with in-stent restenosis. Evid Based Cardiovasc Med. 10:47-8, 2006.

Gurbel PA, Lau WC, Bliden KP, Tantry US. Clopidogrel resistance: Implications for coronary stenting. Curr Pharm Des. 12:1261-9, 2006

Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.Thromb Res. 2006 Jun 26; [Epub ahead of print]

Gurbel PA, Tantry US. Drug insight: Clopidogrel non-responsiveness. Nature ClinPract Cardiovasc Med. 3:387-95, 2006.

Gurbel PA, Tantry US. Aspirin and Clopidogrel Resistance: Considerations and management. J Interv Cardiol. 19:439-48, 2006.

Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm Res. 23:2691-708, 2006

Wiviott SD, Tantry US, Gurbel PA. Clinical applications of antiplatelet therapy. Rev Cardiovasc Med. 7:130-46, 2006

Tantry US, Bliden KP, Gurbel PA. Prasugrel. Expert Opin Investig Drugs. 15:1627-33, 2006.

Gurbel PA, Tantry US. Clopidogrel Resistance? Thromb Res. 2006 Nov 14 [Epub ahead of print]

Gurbel PA, Bliden KP, Tantry US. Effect of  clopidogrel with and without eptifibatide on tumor 
necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation: results
from the CLEAR PLATELETS-1b study. J Am Coll Cardiol. 48: 2186-91, 2006.

Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O�Shaughnessy C, Ball MW, Turco M,  Applegate
RJ, Gurbel PA, et al.for the ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 48:2440 � 2447, 2006.

Tantry US, Etherington A, Bliden KP, Gurbel PA. Antiplatelet therapy: Current strategies and future
 trends. Future Cardiology 2:343-366, 2006

Gurbel PA. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med. Suppl 4:S20-8, 2006.

Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 49:657-66, 2007.
 
Tantry US, Bliden KP, Gurbel PA.  AZD6140. Expert Opin Investig Drugs.16:225-9, 2007

Gurbel PA, Bliden KP, DiChiara J, Gesheff T, R.N., Chaganti S, Etherington A, M.D., Tantry US.
Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation,final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients. Thromb Res, 2007 (epub March 30)

Gurbel PA, Bliden KP, Tantry US. Evidence that pre-existent variability in platelet response to ADP accounts for �clopidogrel resistance�: a rebuttal . J Thromb Haemost. 5:1087-88, 2007

Gurbel PA, Tantry US. Stent thrombosis; role of compliance and non-responsiveness to antiplatelet therapy. Rev Cardiovasc Med. 8:S19-S26, 2007

Peer-reviewed articles (in press)

Gilstad JR, Andersen RE, Gambert SR, Gurbel PA. Relationship between age and platelet activation in patients with stable and unstable angina. J Gerontology., 2006.
 
DiChiara, J, Bliden, KP, Tantry US, Chaganti SK, Kreutz  R Gesheff, TB Kreutz Y, Gurbel PA.
Platelet aspirin responsiveness measured by VerifyNow: correlation with multiple
         methods and identification of a high platelet reactivity phenotype. Platelets., 2007

Gurbel PA, Bliden KP, DiChiara J, Gesheff T, R.N., Chaganti S, Etherington A, M.D., Tantry US.
Evaluation of dose-related effects of aspirin on platelet function:results from the ASpirin-Induced
Platelet EffeCT (ASPECT) study. Circulation., 2007

Kreutz  RP, Tantry US, Bliden KP, Gurbel PA. Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coag Fibrinol. 2007

Gurbel PA, DiChiara J, Tantry US. Antiplatelet therapy after implantation of drug-eluting stents:
duration, resistance, alternatives, and management of surgical patients. Am J Cardiol. 2007

Peer-reviewed Abstracts

Tantry U, Bliden K, Yoho J, Hayes K, Kreutz R, Gurbel PA. The VASP index: A new reliable method to detect response variability after clopidogrel. J Thromb Haemost, 2005.

Gurbel PA, Bliden KP, Hayes KM, Kreutz Y, Herzog WR, Tantry U. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Thromb Haemost, 2005.

Bliden KP, Tantry U, Guyer K, Bassi A, Zaman K, Gurbel PA. Thrombelastography is a useful predictor of stent thrombosis. J Thromb Haemost, 2005.

Bliden KP, Tantry U, Guyer K, Hayes K, Yoho J, Gurbel PA. High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. J Thromb Haemost, 2005.

Tantry U, Bliden KP, Yoho J, Hayes K, Kreutz Y, Gurbel PA. Over estimation of aspirin resistance: 1 out of 143 patients exhibiting true aspirin resistance. J Thromb Haemost, 2005.

Tantry U, Bliden KP, Yoho J, Hayes K, Kreutz R, Gurbel PA. A new method to measure P2Y12 receptor expression on the surface of human platelets: Effect of clopidogrel. J Thromb Haemost, 2005.

Bliden KP, Tantry U, Guyer K, Herzog W, Kreutz R, Gurbel PA. Hypercoaguability measured by TEG strongly predicts recurrent ischemic stents post coronary stenting. J Thromb Haemost, 2005.

Gurbel PA, Bliden KP, Fissha M, Yoho J, Kreutz R, Zaman K, Tantry U. High dose clopidogrel and eptifibatide:  The optimum strategy to prevent myocardial necrosis in elective stenting? Results from the CLEAR PLATELET Study. J Thromb Haemost, 2005.

Kreutz RP, Bliden KP, Tantry U, Gurbel PA. Viral respiratory tract infections increase platelet reactivity and activation. An explanation for higher rates of myocardial infarction and stroke during viral illness. J Thromb Haemost, 2005.

Tantry U, Bliden KP, Yoho J, Hayes K, Kreutz Y, Gurbel PA. The over estimation of aspirin resistance. Eur Heart J 2005.

Gurbel PA, Bliden KP, Plantholt K, Gesheff T, Fissha M, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the CLEAR PLATELET study. Eur Heart J, 2005.

Tantry US, Bliden KP, Gurbel PA. The P2Y12 reactivity ratio: A new method to detect response variability after clopidogrel. Eur Heart J, 2005.

Gurbel PA, Bliden KP, Yoho J, Zaman K, Kreutz R, Tantry U. The effect of High Vs. standard dose clopidogrel loading with and without eptifibatide on markers of inflammation.  Results from the CLEAR PLATELETS Study. Circulation. 2005. 112;II-75;447.

Gurbel PA, Bliden KP, Tantry U. Insufficient P2Y12 receptor occupancy by clopidogrel and stent thrombosis. Circulation. 2005. II-685;3211.

Gurbel PA, Bliden KP, DiChiara J, Chaganthi S, Tantry U. Platelet aspirin resistance in patients with coronary artery disease is rare at all aspirin doses when measured by COX-1 specific assays. J Am Coll Cardiol. 2006:47;288A.

Tantry U, Gurbel PA , Bliden KP,  DiChiara J, Chaganthi S. Inconsistency in the prevalence of platelet aspirin resistance as measured by COX-1 non-specific assays in patients treated with 81,162, and 325 mg aspirin. J Am Coll Cardiol. 2006:47;290A..

Vishnupriya KS, Bliden KP, Kreutz RP, Tantry U, Gurbel PA. The relation of high ex vivo thrombogenic potential to high ischemic risk in African American women undergoing stenting. J Am Coll Cardiol. 2006:47;2B.

Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry U. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel; A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. . J Am Coll Cardiol. 2006:47;16B.

Vishnupriya K, Fissha M, Bliden KP, Tantry US. Increased risk in patients with high platelet aggregation on chronic clopidogrel therapy undergoing repeat PCI; Is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2006:47;45B.

Gurbel PA, Zaman K, Bliden KP, Tantry U. Maximum clot strength is a novel and highly predective indicator of restenosis; A potential future measure to determine who needs antiproliferative therapy and how much. J Am Coll Cardiol. 2006:47;43B.

Gurbel PA, Bliden KP, Dichiara J, Chaganti S, Tantry US. Platelet aspirin resistance measured by VerifyNow identifies a high platelet reactivity phenotype. Eur Heart J, 2006.

Gurbel PA, Bliden KP, Dichiara J, Chaganti S, Gesheff T, Fissha M, Tantry US. Platelet Aspirin Resistance in Patients With Coronary Artery Disease is Rare at All Aspirin Doses When Measured by COX-1 Specific Assays. Eur Heart J, 2006

Bliden KP, Tantry US, Gesheff T, Guyer K, Gurbel PA. Inconsistency in the Prevalence of Platelet Aspirin Resistance as Measured by Various Point-of-Service Assays in Stable Cardiovascular Patients Treated with 81, 162 and 325 mg Aspirin. Eur Heart J, 2006

Tantry US, Bliden KP, Dichiara J, Chaganti S, Gurbel PA. Evidence of a Non-COX-1 mediated Dose dependent Effect of Aspirin in Platelets: results from the ADEPT study. Eur Heart J, 2006

Bliden KP, Tantry US, Gesheff T, Guyer K, Gurbel PA. Increased Risk in Patients with High Platelet Aggregation on Chronic Clopidogrel Therapy Undergoing Repeat PCI: Is the Current Antiplatelet Therapy Adequate? Eur Heart J, 2006.
Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US. Delayed Thrombin-Induced Platelet-Fibrin Clot Generation by Clopidogrel. Eur Heart J, 2006.

Gurbel PA, Bliden KP, Zaman K, Hosamane B, Tantry US. High Platelet-Fibrin Mediated Clot Strength Measured by Thrombelastography Predicts Stent Restenosis. Eur Heart J, 2006.

Gurbel PA, Bliden KP, Tantry US. A Mechanistic Link between High Platelet Reactivity, Inflammation Marker Release and Myonecrosis in Patients Undergoing Stenting:CLEAR PLATELETS-Ib Study. Eur Heart J, 2006.

Bliden KP , Tantry US, DiChiara J, Gesheff T, Javillo J, Kreutz Y,Gurbel PA, Dose dependent effect of Aspirin in Platelets: Results from the ADEPT Study. Circulation 114:II-72, 2006.

Gurbel PA, Bliden KP, Gesheff T, Kreutz Y, Tantry US. A Mechanistic Link between High Platelet Reactivity, Inflammation Marker Release and Myonecrosis in Patients Undergoing Stenting:CLEAR PLATELETS-Ib Study. Circulation 114:II-249, 2006.